What Doctors Will Prescribe Ozempic for Weight Loss

Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide prescriptions for weight loss have grown from a niche diabetes treatment to a mainstream therapy. In 2023, approximately 9 million Americans filled prescriptions for GLP-1 receptor agonists, with semaglutide accounting for the majority of that volume. Understanding which medical professionals can prescribe this medication and what the approval landscape looks like helps patients access treatment efficiently.

Types of Doctors Who Prescribe Semaglutide for Weight Loss

Primary care physicians—including family medicine doctors and internists—represent the largest group of semaglutide prescribers today. These clinicians have the legal authority to prescribe FDA-approved and compounded medications for off-label weight management, provided they document medical necessity and patient suitability. Many primary care practices now include weight loss management as a core service line, especially in regions with high obesity prevalence.

Board-certified obesity medicine specialists hold the American Board of Obesity Medicine (ABOM) credential and receive specialized training in pharmacological weight management. These physicians often serve as referral specialists when patients require complex case management or have comorbidities like metabolic syndrome. Despite their expertise, obesity medicine specialists represent fewer than 1,500 board-certified practitioners nationwide, creating access barriers for many patients.

Cardiologists increasingly prescribe semaglutide to high-risk cardiac patients because the medication reduces cardiovascular events independent of weight loss alone. Clinical trials demonstrate that semaglutide reduces heart attack and stroke risk in patients with established cardiovascular disease, making it a therapeutic option beyond traditional weight loss indications. This expansion reflects the growing recognition of obesity as a cardiovascular risk factor.

How Semaglutide Works for Weight Loss

Semaglutide functions as a GLP-1 receptor agonist, meaning it activates the glucagon-like peptide 1 receptor in the brain and gut. This activation increases satiety signals, slowing gastric emptying and reducing overall caloric intake. The medication also stabilizes blood sugar levels, which helps curb cravings for high-glycemic foods and reduces energy fluctuations throughout the day.

Clinical trials show semaglutide users lose an average of 15–22% of baseline body weight over 68 weeks, compared to 2–3% in placebo groups. The STEP trials (Semaglutide Treatment Effect in People with Obesity) enrolled over 4,500 patients across four studies, consistently demonstrating dose-dependent weight loss and metabolic improvements. These results represent a meaningful therapeutic effect for individuals struggling with diet and exercise alone.

Beyond weight reduction, semaglutide improves several metabolic markers including fasting glucose, HbA1c, and triglycerides. Patients report reduced appetite within 3–7 days of starting therapy, though the full weight loss plateau typically occurs around week 16–20. The medication's effects persist only while patients remain on treatment, making long-term adherence central to sustained weight management.

FDA Approval Status and Off-Label Prescribing

The FDA approved semaglutide under the brand name Wegovy in 2021 specifically for chronic weight management in adults with obesity or overweight with weight-related comorbidities. This approval marked the first GLP-1 medication explicitly indicated for weight loss in non-diabetic populations. The approved formulation is a once-weekly subcutaneous injection delivered in a prefilled pen.

Physicians may also prescribe semaglutide off-label for weight loss using the diabetes formulation (Ozempic brand) or through licensed compounding pharmacies. Off-label prescribing is legal and common in medicine when clinicians determine a medication addresses a patient's medical need based on evidence. Compounded semaglutide provides a cost-effective alternative to branded versions, with PlexusDx Compounded Semaglutide Injection at $189/mo month-to-month, or from $149/mo on the 6-month plan across all three commitment tiers.

Insurance coverage varies significantly by plan and formulary status. Many commercial plans restrict or deny coverage for weight loss indications, requiring patients to pay out-of-pocket or seek compounded alternatives. PlexusDx serves all 50 states with no insurance requirement and accepts HSA and FSA funds, making personalized semaglutide therapy accessible regardless of insurance status.

Choosing the Right Provider and Starting Treatment

Selecting a semaglutide prescriber requires evaluating several factors: clinical expertise in weight management, availability for ongoing monitoring, willingness to address side effects, and support for behavioral modifications. Providers experienced with GLP-1 therapy understand dose titration protocols, recognize nausea and gastrointestinal side effects as manageable rather than reasons to discontinue, and adjust management strategies accordingly.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR (rs1800437) and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Starting semaglutide typically requires a medical history, weight and vital signs assessment, and baseline labs including fasting glucose and kidney function. Most prescribers begin at the lowest dose (0.25 mg weekly for injections or 3–7 mg daily for oral formulations) and increase gradually every 4 weeks to minimize gastrointestinal side effects. Treatment success depends on combining pharmacotherapy with dietary modifications, regular physical activity, and behavioral support—a comprehensive approach that yields sustained, meaningful weight reduction.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437 , FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Can my primary care doctor prescribe semaglutide for weight loss?

Yes. Primary care physicians have full legal authority to prescribe semaglutide for weight loss management when medically indicated. Many family medicine and internal medicine practices now offer weight loss programs that include GLP-1 therapy, making semaglutide accessible through your established medical relationship.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide but target different conditions. Wegovy is FDA-approved specifically for weight loss in non-diabetic adults, while Ozempic is approved for type 2 diabetes. Physicians legally prescribe Ozempic off-label for weight loss. Compounded semaglutide from licensed 503A pharmacies offers another cost-effective option, with PlexusDx pricing at $189/mo month-to-month, or from $149/mo on the 6-month plan.

How much does semaglutide treatment cost without insurance?

PlexusDx Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan)—your dose may need to go up, but your price won't. HSA and FSA accounts are accepted, and no insurance is required. This pricing covers access to all strength levels across three commitment tiers.

What side effects should I expect with semaglutide?

Common side effects include nausea, constipation, and reduced appetite—most resolve within 2–4 weeks as the body adjusts. Serious side effects are rare but may include pancreatitis or gallbladder issues. Experienced providers manage side effects through dose titration, dietary adjustments, and behavioral strategies rather than discontinuing therapy.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to Ozempic or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Weight Loss Drugs Like Ozempic
• Ozempic Weight Loss Before And After Pictures

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.